NASDAQ:CVKD Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis $0.98 +0.04 (+4.41%) Closing price 04:00 PM EasternExtended Trading$1.00 +0.02 (+1.52%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Cadrenal Therapeutics Stock (NASDAQ:CVKD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cadrenal Therapeutics alerts:Sign Up Key Stats Today's Range$0.94▼$1.0050-Day Range$0.87▼$1.7552-Week Range$0.82▼$13.75Volume80,671 shsAverage Volume204,747 shsMarket Capitalization$3.52 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingHold Company Overview Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) is a clinical-stage biopharmaceutical company focused on developing therapies for patients who require long-term anticoagulation. The company’s lead product candidate is tecarfarin, an investigational oral anticoagulant designed for individuals with implanted mechanical heart valves and other mechanical circulatory support devices. Tecarfarin is a vitamin K antagonist intended to address challenges associated with existing anticoagulant therapy, including drug interactions and changes in a patient’s metabolism. Cadrenal has evaluated the candidate in clinical studies and has pursued its development for patients with mechanical heart valves and left ventricular assist devices, populations that may require lifelong anticoagulation to reduce the risk of blood clots. Cadrenal Therapeutics is based in Ponte Vedra Beach, Florida, and was founded by Quang X. Pham, who serves as the company’s chief executive officer. The company’s development activities are primarily focused on advancing tecarfarin through clinical and regulatory evaluation in the United States.AI Generated. May Contain Errors. Read More Cadrenal Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScoreCVKD MarketRank™: 2.205029013535 of 5 starsCadrenal Therapeutics scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCadrenal Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialCadrenal Therapeutics has a consensus price target of $13.00, representing about 1,219.8% upside from its current price of $0.99.Amount of Analyst CoverageCadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Cadrenal Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($3.86) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cadrenal Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cadrenal Therapeutics is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCadrenal Therapeutics has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cadrenal Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.24% of the float of Cadrenal Therapeutics has been sold short.Short Interest Ratio / Days to CoverCadrenal Therapeutics has a short interest ratio ("days to cover") of 0.91, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cadrenal Therapeutics has recently increased by 165.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCadrenal Therapeutics does not currently pay a dividend.Dividend GrowthCadrenal Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.27 News SentimentCadrenal Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cadrenal Therapeutics this week, compared to 4 articles on an average week.Search Interest1 people have searched for CVKD on MarketBeat in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cadrenal Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders14.59% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions7.92% of the stock of Cadrenal Therapeutics is held by institutions.Read more about Cadrenal Therapeutics' insider trading history. Receive CVKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVKD Stock News HeadlinesCadrenal Therapeutics IncOctober 27 at 8:15 PM | markets.ft.comCadrenal Therapeutics Begins Strategic Review Following FDA Alignment On CAD-1005October 7, 2026 | rttnews.com$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightforward 3-step approach to trading same-day options, with entry, exit and max loss set before you ever place a trade. Plain English, no complicated math, done by market close. The price may return to 29.97 as soon as tomorrow.October 30 at 1:00 AM | Profits Run (Ad)Cadrenal Therapeutics Begins Strategic Review of Orphan PortfolioOctober 7, 2026 | tipranks.comCadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory TherapeuticsOctober 7, 2026 | globenewswire.comCadrenal Shareholders Approve Equity Plan and Board ChangesSeptember 29, 2026 | tipranks.comCadrenal Therapeutics CEO to Present at Lytham Partners Fall 2026 Investor Conference September 21, 2026 | quiverquant.comQCadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor ConferenceSeptember 21, 2026 | globenewswire.comSee More Headlines CVKD Stock Analysis - Frequently Asked Questions How have CVKD shares performed this year? Cadrenal Therapeutics' stock was trading at $6.78 at the beginning of the year. Since then, CVKD shares have decreased by 85.5% and is now trading at $0.9850. How were Cadrenal Therapeutics' earnings last quarter? Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced its earnings results on Thursday, August, 13th. The company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.28. When did Cadrenal Therapeutics IPO? Cadrenal Therapeutics (CVKD) raised $7 million in an IPO on Friday, January 20th 2023. The company issued 1,400,000 shares at a price of $5.00 per share. Who are Cadrenal Therapeutics' major shareholders? Top institutional investors of Cadrenal Therapeutics include Courier Capital LLC (1.11%). View institutional ownership trends. How do I buy shares of Cadrenal Therapeutics? Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cadrenal Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cadrenal Therapeutics investors own include Palantir Technologies (PLTR), Tesla (TSLA), NVIDIA (NVDA), Invesco QQQ (QQQ), Walt Disney (DIS), Oracle (ORCL) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/13/2026Today10/30/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CVKD's financial health is in the Red zone, according to TradeSmith. CVKD has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CVKD CIK1937993 Webwww.cadrenal.com Phone904-300-0701FaxN/AEmployees5Year Founded2022Price Target and Rating Average Price Target for Cadrenal Therapeutics$13.00 High Price Target$13.00 Low Price Target$13.00 Potential Upside/Downside+1,219.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($4.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.24 million Net MarginsN/A Pretax MarginN/A Return on Equity-406.41% Return on Assets-273.80% Debt Debt-to-Equity RatioN/A Current Ratio3.73 Quick Ratio3.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book0.84Miscellaneous Outstanding Shares3,570,000Free Float3,047,000Market Cap$3.52 million OptionableNot Optionable Beta1.93 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CVKD) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
